Inside informationEnglish
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 31/01/2025, 07:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 115900_20250131